Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials.

CONCLUSION: Our meta-analysis has indicated that SGLT2 inhibitors do not increase risk of bone fracture compared with placebo in patients with T2DM. However, these findings now need to be confirmed in well-designed RCT studies.
PMID: 30738154 [PubMed - as supplied by publisher]

Source: Diabetes and Metabolism - February 6, 2019 Category: Endocrinology Authors: Cheng L, Li YY, Wen H, Bai F, Hao HR, Yu WN, Mao XM Tags: Diabetes Metab Source Type: research